Lobe Sciences' Nov. 30 cash at $5.99-million

Executive Summary

• Lobe Sciences Ltd. reported unaudited financial results for the first quarter of fiscal 2026 (ended November 30, 2025), showing a significant increase in R&D expenditures and net loss compared to the prior year period.
• The company highlighted accelerated research and development activities, specifically advancing its lead program L-130 (psilocin mucate) through preclinical studies and regulatory filings for chronic cluster headache and opioid use disorder.
• Lobe maintained a cash position of approximately $6.0 million and net working capital of over $4.0 million, while implementing tight cash controls to support increased development activity and the addition of scientific resources.

Key Details

• Financial Highlights (Q1 2026 vs. Prior Year):
  • Cash: Totalled $5,991,614 as of Nov. 30, 2025.
  • Short-term Investments: Totalled $1,025,098 as of Nov. 30, 2025.
  • Net Working Capital: Totalled $4,047,891 as of Nov. 30, 2025.
  • R&D Expenses: Increased to $982,087 for the quarter ended Nov. 30, 2025, compared to $7,551 in the same period last year.
  • Operating Cash Flow: Used $579,006 for the quarter ended Nov. 30, 2025, compared to $243,068 used in the prior year period.
  • Net Loss: $1,305,827 for the quarter ending Nov. 30, 2025, compared to $800,634 for the same period last year.
• Operational Updates:
  • L-130 (Cynaptec Pharmaceuticals): Majority of R&D expenditures incurred through subsidiary Cynaptec (64% owned by Lobe). Activities included advancing L-130 (psilocin mucate) through preclinical studies and regulatory activities supporting proof of concept and Investigational New Drug (IND) filings.
  • Phase 1a Status: A Phase 1a clinical study in healthy volunteers and comprehensive preclinical studies have been completed outside the United States. The company is engaging with the U.S. FDA through pre-IND interactions.
  • S-100 (Altemia Inc.): Continued focus on the early-stage drug candidate for sickle cell disease. The formulation consists of triglyceride esters of DHA and EPA with a patented absorption-enhancing blend.
  • Commercialization: Limited preliminary commercialization activities continued for a proprietary medical food for sickle cell disease patients, focusing on evaluating third-party reimbursement pathways in Georgia.
  • Staffing: Added additional scientific resources to support advancement of research and development efforts toward Phase 1 and Phase 2 clinical activities.
• Strategic Overview:
  • Lobe is advancing two main programs: L-130 for chronic cluster headache (lead) and opioid use disorder via Cynaptec Pharmaceuticals; and S-100 for sickle cell disease via Altemia Inc.
  • The company is evaluating other strategic opportunities consistent with its business strategy.

Notable Quotes

• "During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D [research and development] expenditures increasing to just under $1-million as we advanced our core programs through Cynaptec Pharmaceuticals Inc.," said Dr. Fred Sancilio, chief executive officer of Lobe Sciences.
• "This progress reflects our transformative approach to drug development of next-generation serotonergic agents, combining our advanced pharmaceutical development expertise, focused subsidiary-level execution with centralized scientific and regulatory core competencies."
• "Importantly, this increased level of activity was achieved alongside improved operating efficiency, underscoring the benefits of our shared services model. We believe this disciplined and scalable approach positions the company to continue advancing development initiatives while maintaining a strong financial foundation."